Furthermore, serum LCN-2 is significantly increased and associated with early-stage renal damage as well as the incidence of CAP in patients with T2DM, and LCN-2 may be a potential biomarker related to the progression of disease in patients with T2DM. This evidence concerns the gene LCN2 and type 2 diabetes mellitus.